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ABSTRACT
Introduction Ductal carcinoma in situ (DCIS) of the breast
is a non-obligate precursor of invasive breast cancer (IBC).
Many DCIS patients are either undertreated or overtreated.
The overarching goal of the study described here is to
facilitate detection of patients with DCIS at risk of IBC
development. Here, we propose to use risk factor data
and formalin-fixed paraffin-embedded (FFPE) DCIS tissue
from a large, ethnically diverse, population-based cohort
of 8175 women with a first diagnosis of DCIS and followed
for subsequent IBC to: identify/validate miRNA expression
changes in DCIS tissue associated with risk of subsequent
IBC; evaluate ipsilateral IBC risk in association with two
previously identified marker sets (triple immunopositivity
for p16, COX-2, Ki67; Oncotype DX Breast DCIS score);
examine the association of risk factor data with IBC risk.
Methods and analysis We are conducting a series of
case–control studies nested within the cohort. Cases
are women with DCIS who developed subsequent IBC;
controls (2/case) are matched to cases on calendar year
of and age at DCIS diagnosis. We project 485 cases/970
controls in the aim focused on risk factors. We estimate
obtaining FFPE tissue for 320 cases/640 controls for the
aim focused on miRNAs; of these, 173 cases/346 controls
will be included in the aim focused on p16, COX-2 and
Ki67 immunopositivity, and of the latter, 156 case–control
pairs will be included in the aim focused on the Oncotype
DX Breast DCIS score®. Multivariate conditional logistic
regression will be used for statistical analyses.
Ethics and dissemination Ethics approval was obtained
from the Institutional Review Boards of Albert Einstein College
of Medicine (IRB 2014-3611), Kaiser Permanente Colorado,
Kaiser Permanente Hawaii, Henry Ford Health System, Mayo
Clinic, Marshfield Clinic Research Institute and Hackensack
Meridian Health, and from Lifespan Research Protection
Office. The study results will be presented at meetings and
published in peer-reviewed journals.

INTRODUCTION
Ductal carcinoma in situ (DCIS), which
arises in the terminal duct lobular unit of the
breast,1 is considered to be a non-
obligate

Strengths and limitations of this study
►► This is a large, multicentre population-based cohort

study of women with ductal carcinoma in situ (DCIS)
of the breast designed to identify the associations
of clinical, epidemiological and pathological factors,
and of molecular changes in DCIS tissue, with risk of
subsequent invasive breast cancer.
►► The study will have considerable statistical power.
►► Although some individuals may be misclassified with
respect to exposure (ie, their status with respect to
the results of the molecular assays), the study methods are highly sensitive and reproducible, and laboratory staff are blinded to case–control status.
►► Generalisation of the study findings to other populations will require caution, but cases and controls are
selected independently of molecular markers, so it
is unlikely that unavailability or unsuitability of tissue
for analysis will bias the study results.

precursor of invasive breast cancer (IBC).2
About 5%–14% of patients diagnosed with
DCIS and treated with breast-
conserving
therapy, with or without radiation, experience an ipsilateral IBC and 1%–6% experience a contralateral IBC over a period of 10
years.3–5 Overall, compared with women in
the general population, women with a history
of DCIS have anywhere from a 1.5-fold to a
10-fold increase in risk of subsequent IBC.3 6–9
The introduction of screening mammography has led to a substantial increase in
the detection of DCIS over the past 2–3
decades.2 However, the treatment of DCIS
remains variable, and many DCIS patients
are either undertreated or overtreated.10 11 In
this regard, there is a critical need for elucidation of the molecular differences between
lesions that are associated with risk of IBC
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development and those that are not, as this may help
not only to reduce the occurrence of IBC, but also to
prevent overtreatment of patients with relatively low risk
of IBC.12 13
Gene expression profiling and immunohistochemical
analysis of IBCs have led to improvements in prediction of
their clinical behaviour.14–16 Given that DCIS is associated
with increased risk of IBC development,10 we hypothesise
that study of molecular changes in DCIS may similarly
help to identify novel biomarkers that predict IBC risk. In
this regard, there is some evidence that the Oncotype DX
Breast DCIS score®, derived from a multigene expression
assay that incorporates genes related to proliferation, as
well as PR and GSTM1, and five reference genes, predicts
risk of subsequent ipsilateral IBC.10 17 Similarly, triple
positivity for immunohistochemically detected expression of p16, COX-2 and Ki67 has also been associated with
increased risk of ipsilateral IBC.18 However, these findings
require confirmation. Furthermore, we hypothesise that
novel prognostic (and ultimately predictive) markers may
emerge from assessment in DCIS tissue of gene expression patterns on a global scale. Of relevance here are
microRNAs (miRNAs), small regulatory noncoding RNAs
that control gene expression19 20 and that, when dysregulated, contribute to the development of breast cancer.21 22
Against this background, our overarching goal is to
facilitate the detection of patients with DCIS at risk of
IBC development. To this end, we propose to use clinical, epidemiological and histopathological data, and
archival formalin-fixed paraffin-embedded (FFPE) tissue,
from a large, ethnically diverse, population-based multicentre cohort of 8175 patients initially diagnosed with
DCIS in community-based hospitals and health plans and
followed for subsequent IBC development. Our specific
aims are to identify/validate miRNA expression changes
in DCIS tissue associated with risk of subsequent IBC,
to evaluate ipsilateral IBC risk in association with two
previously identified marker sets (triple immunopositivity for p16, COX-2, Ki67; the Oncotype DX Breast
DCIS score), and to examine the association of clinical,
epidemiological and histopathological variables with IBC
risk. Furthermore, we will store genomic DNA (extracted
simultaneously with RNA) for subsequent study of somatic
genetic changes related to risk of IBC.
METHODS
Study population and design
We assembled a multicentre population-based cohort of
8175 women aged ≥18 years, with no history of IBC, who
received a first histological diagnosis of DCIS between
12 January 1987 and 20 December 2016. The study
started on 15 September 2017 and will continue until 31
July 2023 at the earliest. The cohort was constructed by
including DCIS patients from six large community-based
integrated healthcare delivery systems across the USA:
Henry Ford Health System (Detroit, Michigan, USA),
Kaiser Permanente (KP) Colorado (Denver, Colorado,
2

Table 1

Cohort numbers, overall and by centre

Site

Calendar
period
of DCIS
diagnosis

Henry Ford
1991–2015
KP Colorado 2006–2016

No of
subjects
with DCIS

No of
subsequent
cases of
invasive breast
cancer*

1737
1154

149
33
65

KP Hawaii

1987–2016

936

Marshfield

1990–2016

1233

66

Mayo

1988–2016

1358

108

Montefiore
Total

1994–2016
1987–2016

1757
8175

64
485

*For follow-up until 2020.
DCIS, Ductal carcinoma in situ.

USA), KP Hawaii (Honolulu, Hawaii, USA), Marshfield
Clinic (Marshfield, Wisconsin, USA), Mayo Clinic (Rochester, Minnesota, USA) and Montefiore Medical Center
(Bronx, New York, USA) (table 1). Collectively, the participating centres provide comprehensive medical care for
patients who are broadly representative of the racial/
ethnic and socioeconomic distribution of the underlying
populations.
Cohort follow-up and ascertainment of IBC cases
Using the extensive electronic medical record (EMR)
and administrative databases at each institution, patients
are followed passively from the date of their DCIS diagnosis until the date of development of subsequent IBC,
death, health plan disenrollment or the end of follow-up,
whichever comes first. In each centre, the occurrence
of subsequent IBC (ipsilateral or contralateral) in the
DCIS cohort is ascertained by linking records from the
cohort to the respective tumour registry and/or to other
EMR data. Given that all participating centres provide
integrated care, all healthcare procedures for patients
are typically conducted within the health systems, and
any outside services are captured through reimbursement/claims data. This integrated model also facilitates
the collection of tumour tissue, which usually is stored
centrally. The number of IBCs ascertained in each centre
and the calendar period of the DCIS diagnoses are shown
in table 1.
Nested case–control studies
We are conducting our investigation as a series of case–
control studies nested in the DCIS cohort.
Cases are women with a first diagnosis of DCIS and
with a subsequent diagnosis of IBC at least 6 months
after the index DCIS diagnosis (table 1) (women treated
by mastectomy who develop subsequent chest wall IBC
are not included in the study). Controls are women
with a first diagnosis of DCIS, with no history of breast
cancer, with no history of bilateral mastectomy prior to
the date of diagnosis of IBC for the corresponding case,
Rohan TE, et al. BMJ Open 2021;11:e053397. doi:10.1136/bmjopen-2021-053397
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and who were alive but had not developed IBC during
the same follow-up period as that for the corresponding
case. For each of the DCIS subjects who developed a
subsequent IBC (cases), we select two controls using
risk-set sampling. Each control is individually matched
to the corresponding case on calendar year of (mostly
within ±1 year) and age at (generally ±1 year) diagnosis
of DCIS. We have limited the number of matching variables so as to retain flexibility in the analysis. Nevertheless, we are measuring potentially relevant variables (eg,
treatment, adjuvant endocrine therapy) and will be able
to adjust for such variables in the analysis. We expect to
include 485 cases and 970 controls in the aim focused
on clinical/epidemiological/histopathological variables and IBC risk. We project that we will obtain FFPE
tissue for 320 of the cases and 640 controls, and these
subjects will be included in the aim focused on miRNAs;
of these, 173 cases/346 controls will be included in the
aim focused on p16, COX-2 and Ki67 immunopositivity,
and of the latter, 156 case–control pairs will be included
in the aim focused on the Oncotype DX Breast DCIS
score.
Risk factor data
We use the EMR to extract data on variables such as age at
and year of DCIS diagnosis; family history of breast cancer;
height and weight; method of DCIS detection (palpation,
mammography); tumour laterality; tumour size; treatment (including breast conserving surgery, radiotherapy
and hormonal therapy); menstrual and reproductive
history; use of oral contraceptives and hormone replacement therapy; and cigarette and alcohol consumption.
The data are being obtained in a standardised manner at
all participating institutions by using a chart abstraction
manual to guide data abstraction; chart abstractors are
trained centrally in use of the manual. Risk factor data are
being abstracted for all cases and their matched controls,
regardless of whether DCIS tissue is obtained.
Tissue blocks/sections
For the cases and matched controls included in this study,
we attempt to retrieve FFPE DCIS tissue blocks from the
pathology archives of the participating institutions. To
date, DCIS tissue blocks have been obtained for 72% of
the cases; we attempt to obtain DCIS tissue for two controls
per case, replacing potential controls for whom tissue is
unobtainable. For cases with subsequent contralateral
IBC (and their matched controls), four 5 μm sections (for
oestrogen receptor (ER), progesterone receptor (PR),
human epidermal growth factor receptor 2/neu (HER2/
neu) and H&E), plus 16 ten μm sections (for RNA/DNA
extraction), are cut from each FFPE block; for cases with
subsequent ipsilateral IBC, 7 five μm sections are cut (for
ER, PR, HER2, p16, COX-2, Ki67, H&E), in addition to 16
ten μm sections. The last of the 5 µm unstained sections
(ie, the section after the sections taken for immunohistochemistry) undergoes H&E staining.
Rohan TE, et al. BMJ Open 2021;11:e053397. doi:10.1136/bmjopen-2021-053397

Experimental methods
All histopathology reviews and laboratory assays are
performed blinded to the case-control status of the study
subjects.
Histopathology/receptor status
H&E sections are reviewed and classified by the study
pathologist (YW) according to standard criteria with
respect to nuclear grade, architectural pattern, necrosis
and microcalcification23; areas of DCIS are circled on the
coverslips (women with DCIS with microinvasion are not
included). The sections stained for ER, PR and HER2/
neu are interpreted in accordance with American Society
of Clinical Oncology/College of American Pathologists
(ASCO-CAP) guidelines.24 25 ER/PR positivity is defined
as ≥1% cells staining positive24 and HER2 positivity is
defined as a score of 3+. For those subjects for whom
tissue blocks cannot be located, we will use information
on histology and receptor status abstracted from the
medical records.
RNA/DNA extraction
Using the H&E section as a guide, the DCIS lesions are
macrodissected from the 16 ten μm unstained sections
and then subjected to co-extraction of RNA and DNA
using our simultaneous TRIzol RNA/DNA extraction
protocol.26 Total RNA is quantified and visually evaluated on an Agilent Bioanalyzer (RNA Nanochip), and
DNA is quantified on a Qubit instrument (dsDNA High
sensitivity assay kit). Stock RNA samples are aliquoted for
sequencing and qPCR experiments. RNA/DNA samples
are stored at −80°C.
MiRNA expression profiling using next-generation sequencing
Using 100 ng of total RNA per sample, batches of 18
samples will be set up in individual ligation reactions
(using T4 RNA ligase 2 truncated K227Q), using 18
different 3’ adenylated barcoded adapters, at 4°C for
16 hours. We will include cases and their matched
controls in the same libraries. Ten unique RNA calibrators (each 22 nucleotides long) without any match to
human or mouse genomes will be spiked at 0.026 nM
into each individual sample ligation, and will be used as
quality and normalisation controls. As a further control,
duplicate DCIS case and control samples selected from
the different libraries will be analysed in three additional
libraries. After 3’ ligation of the barcoded adapters, the
18 reactions will be heat-
deactivated, and the ligated
products will be combined and size-selected on a 15%
polyacrylamide gel (PAGE). The ligated products will
be excised, purified and subjected to a global 5’adapter
ligation. After ligation, the products will be size-selected
on a 12% PAGE, purified and reverse-transcribed. The
cDNA templates will be subjected to a pilot PCR for identification of the appropriate number of amplification
cycles. A final large-scale PCR will be set up, size selected
(2% agarose gel), and sequenced on an Illumina HiSeq
2500 sequencer. Individual libraries will be analysed by
3
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aligning the reads to the human genome and separating
the samples using the 18 different 3’ barcoded adapters.27

processed using the nSolver Software (Nanostring) and
then subjected to further statistical analyses.

Real-time polymerase chain reaction (qPCR) miRNA quantification
for validation of miRNA sequencing findings
100 ng of total RNA will be used to validate expression of
the top 14 differentially expressed miRNAs identified by
sequencing. MiRNA quantification will be performed in
two steps, a single multiplex RT step (14 miRNAs and 2
endogenous controls—RNU6B, RNU44) using Taqman®
reverse transcription kits and Taqman® primer RT pool
(16 genes; Applied Biosystems (ABI)), followed by individual qPCR reactions (16 genes analysed in triplicate)
using Taqman® universal PCR mastermix (No AmpErase;
ABI) and individual PCR primers for each of the 16 genes.
Triplicate miRNA expression measures will be quantified
on a QuantStudio 6-flex real-time qPCR instrument. The
controls will be used for normalisation of miRNA quantification.28 The case-control fold-change (FC) differences
will be calculated using the 2(ΔΔCt) formula.28

Statistical analysis
We will examine the associations between clinical, epidemiological and histopathological variables and risk of
subsequent IBC using multivariate conditional logistic
regression.
To identify/validate miRNA expression changes in
DCIS tissue associated with risk of subsequent IBC, we
are conducting a two-stage study. Based on our feasibility
work, we estimate that we will obtain FFPE DCIS tissue
for at least 320 cases and 640 controls. Of these subjects,
200 cases/400 controls will be included in the discovery
stage and 120 cases/240 controls in the validation stage.
For analysis of the sequencing data (discovery stage),
after quality control and normalisation,29 30 we will first
explore the expression data using heat maps with unsupervised hierarchical clustering via Spearman distance
and complete linkage as well as multidimensional
scaling plots. This will be followed by supervised analyses to compare miRNA levels in the cases and controls
using regression analysis, for example, limma in Bioconductor,31 32 which allows for adjustment for covariates and
paired comparisons. As a complementary approach, we
will model the read counts as a negative binomial distribution to account for discrete sequence data.33 We will
rank differentially expressed miRNAs based on both
statistical significance and degree of FC. These analyses
will allow us to establish a list of candidate miRNAs for
validation, while adjusting for clinical, epidemiological
and histopathological factors.
To address missing information on risk factors, we will
perform multiple imputation after examining the missingness mechanism.34–37 The imputed risk factor data will
be used together with the miRNAs to develop prediction
models using the ‘stack’ method for combining multiply
imputed data into one dataset with proper weights.38
Sensitivity analyses will be performed to evaluate the
robustness of models to imputation approaches. We will
build our model by starting with clinical/epidemiological/histopathological factors and then perform joint
analyses by adding candidate miRNAs to identify the most
important miRNAs. For this purpose, we will use conditional logistic regression with elastic net penalities.39 40
Although it is impossible to accurately predict the
number of miRNAs that will be associated with IBC development, we will choose the top 14 miRNAs for validation
to ensure that we will have sufficient power for validation
given our sample size.41 42 We will perform similar analyses
to those in the discovery stage to validate the association
of each candidate miRNA with risk of IBC. Additionally,
we will evaluate the potential clinical utility of the identified miRNAs from the final elastic regression model
obtained in the discovery stage by calculating the area
under the receiver-operating characteristic curve (AUC)
and its SD.43 44 The difference in AUCs between models
with and without the identified miRNAs will be calculated

p16, COX-2 and Ki67 immunohistochemistry
Slides (5 µm sections) from batches of eight case–control
triplets (cases with subsequent ipsilateral IBC) are deparaffinised, rinsed in graded alcohol, heated to 96°C for
20 min in 10 mM sodium citrate buffer (pH 6.0), and
placed into a Dako Autostainer Plus for processing.
Endogenous peroxidase activity is quenched using 3%
hydrogen peroxide in 1xPBS for 10 min. Blocking is
performed by incubating sections in 5% normal donkey
serum with 2% BSA for 30 min. The primary antibodies
for p16 antigen (Fisher Scientific antibody Clone D25,
Catalog# MA5-17142) used at 1:5000, for Ki67 antigen
(Dako antibody, Clone MIB-
1,Catalog# M7240) used
at 1:200, and for COX-2 antigen (Dako Clone antibody
CX-294, Catalog# M361701-2) used at 1:200, all diluted in
antibody diluent, are incubated for 1 hour. The sections
are stained using a labelled polymer-
HRP anti-
mouse
antibody (Dako Envision System-HRP (DAB)) for 30 min
to localise the antibody bound to the antigen, with diaminobenzidine as the final chromogen. After washes, the
sections are lightly counterstained with haematoxylin
and mounted in Permount. All immunohistochemistry is
performed separately for each antibody and thus requires
three 5 µm sections/specimen. The p16, COX-2, and Ki67
stained sections are evaluated as described elsewhere.18
Oncotype DX DCIS score evaluation using Nanostring
Given cost considerations, it is not feasible to use the
Oncotype DX Breast DCIS score® in this study. Therefore, as an alternative, expression of the 12 genes from the
Oncotype DX DCIS assay plus three additional controls
(MRPL19, COX-2, p16) and one internal control (18 s
rRNA) will be measured in parallel with expression of 770
other genes using the Nanostring nCounter PanCancer
progression panel. To this end, 100 ng of total RNA from
matched cases (with subsequent ipsilateral IBC) and
controls will be analysed simultaneously. The data will be
4
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and the 95% CI will be estimated using a bootstrap procedure.45 In additional analyses, we will explore the associations of miRNAs with IBC risk by side of IBC (ipsi- and
contralateral) and by type of DCIS (using the St. Gallen
criteria for molecular subtypes).46
We will evaluate the relationship between two previously
examined marker sets (p16, COX-2, and Ki67 protein
expression; Oncotype DX Breast DCIS score®) and ipsilateral IBC risk using conditional logistic regression. For
p16, COX-2 and Ki67 protein expression, IBC risk will
be estimated for subjects positive for all three markers
(compared with all other subgroups combined).18 In
addition, we will explore risk for up to eight subgroups
characterised by the three protein expression markers.
For the Oncotype DX Breast DCIS DCIS score®, we will
instead use the Nanostring nCounter PanCancer progression panel to measure expression of the relevant genes.
Quality control and normalisation will be performed
using nSolver Software (Nanostring). For the analysis of
these data, we will first use similar statistical approaches
to those reported in an earlier study.10 Because the original DCIS score was calculated by giving fixed weights, the
score may not be optimal. Therefore, we will also derive an
alternative DCIS score by building a conditional logistic
regression model that has the best predictive value from
the data. To alleviate the problem of overfitting, 10-fold
cross-validation will be used.47 ROC analyses will be used
to evaluate the improvement in risk prediction as a result
of the addition of the biomarker score to the clinical,
epidemiological and histopathological risk factors. AUCs
with 95% CIs will be estimated and compared using the
bootstrap approach.48
Statistical power
For the proposed analyses of clinical/epidemiological/
histopathological variables, we project a sample size
of 485 cases/970 controls. This will yield 80% power at
α=0.05 to detect ORs between 1.17 and 1.20 at missing
data rates of 0%–20% for a continuous risk factor, and
ORs of 1.38–1.43 at missing rates between 0%–20% for
categorical risk factors (assuming an exposure prevalence
of 0.5).
For our work on miRNAs, we use the following formula
to approximate the minimum FC required to achieve
power (1-β) at statistical significance level (α): [Log(FC)]2=(z1-α/2+zβ)2 [(1/μ+σ2)/n1(1/μ+σ2)/n2], in which μ
is read count, σ is the coefficient of variation of counts
within a group, and n1 and n2 are sample sizes for cases
and controls, respectively.49 We considered a wide range
of expression variation [low (σ=0.1) and high (σ=0.4)]
and expression levels [low (μ=10), moderate (μ=50)
and high (μ=100)]. Table 2 summarises the minimum
FC required to achieve a given power (80%) for fixed
sample sizes for the discovery and validation analyses.
Even under the most conservative scenario considered
[low expression level (read counts as low as 10); high variation within a group (0.4)], we will have 80% power to
identify miRNAs with FCs>1.23 at an overly conservative
Rohan TE, et al. BMJ Open 2021;11:e053397. doi:10.1136/bmjopen-2021-053397

Table 2 The minimum fold-changes required to achieve
80% power for the miRNA analyses

Variation
within a
group (σ)
0.1

0.4

Stage 1 (200
cases/400
controls;
α=0.05/1000)
minimum fold-
change

Stage 2 (120
cases/240
controls;
α=0.05/14)
minimum fold-
change

10

1.15

1.15

50

1.08

1.08

100

1.06

1.06

10

1.23

1.23

50

1.20

1.19

100

1.19

1.19

Expression
level
(µ)

Bonferroni significance level of 0.05/1000 in the discovery
stage. For the validation stage, we will have similar power
to validate markers with FCs>1.23 at a significance level of
0.0036, corresponding to a Bonferroni corrected p value
of 0.05 for 14 independent markers. The FCs needed to
achieve satisfactory power are realistic: our preliminary
data showed that significant miRNAs had FCs in the
range 1.23–5.8. The corresponding FCs for ipsilateral
(54% of all cases) and contralateral cases are 1.34 and
1.37, respectively, magnitudes consistent with findings in
our pilot work.
For the aim focused on p16, COX-2 and Ki67 protein
expression, we expect that 173 of the 320 cases with DCIS
tissue will be available, as we observe that ~54% of subsequent IBCs are ipsilateral. Assuming that the proportion
of triple positive controls is ~9%,10 and with two controls
per case, we will have 80% power to detect an OR of
2.2 for the triple positive group versus the other groups
combined, the same effect size as that observed in the
previous study.18
For the aim focused on the Oncotype DX Breast DCIS
score®, we expect 156 ipsilateral cases, given that in our
pilot work, 90% of RNA extractions yielded sufficient
RNA. Given a conservative assumption of 156 case–
control pairs, we will have 80% power when α=0.05 to
detect an OR of 2.01 per 50 point increase in DCIS score.
This projected OR is smaller than the effect size observed
previously.10
Patient and public involvement
No patient or public involvement.
ETHICS AND DISSEMINATION
Ethics approval was obtained from the Institutional
Review Boards of the Albert Einstein College of Medicine
(IRB 2014-
3611), Kaiser Permanente Colorado, Kaiser
Permanente Hawaii, the Henry Ford Health System, the
Mayo Clinic, the Marshfield Clinic Research Institute,
and Hackensack Meridian Health, and from the Research
Protection Office of Lifespan. The results of this study will
5
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be presented at national and international meetings and
published in peer-reviewed journals.
DISCUSSION
Although women with DCIS are at increased risk of developing subsequent IBC compared with those without
DCIS,3 6–9 most women with DCIS do not go on to
develop IBC. Furthermore, current clinical criteria do
not discriminate well between those who will and will not
develop IBC. Therefore, because the treatment of DCIS
is generally aggressive, many women are treated unnecessarily.11 This highlights the need for better markers of risk
of IBC development. In this regard, we hypothesise that
the molecular analysis of archival DCIS tissue will help
to identify novel molecular markers associated with IBC
risk, and may foster the development of risk stratification
models and targeted therapies.50
To date, very few studies have addressed the identification of biomarkers associated with risk of subsequent
IBC development in women with DCIS, largely because to
do so requires long-term follow-up and almost inevitably
entails use of archival specimens. Our molecular epidemiological study, which will apply state-of-the-art technologies to archival DCIS FFPE tissue for the detection of
molecular changes associated with IBC development in
a large, multicentre population-based cohort of women
initially diagnosed with DCIS, has the potential to provide
insight into the biology of DCIS and to lead to approaches
that will help to differentiate between women who need
and those who do not need enhanced surveillance and
early aggressive treatment.
To investigate the associations of the Oncotype DX
Breast DCIS score® and triple positivity for immunohistochemically detected expression of p16, COX-2 and Ki67
with risk of subsequent IBC, we will restrict attention to ipsilateral IBC, as per previous investigations in this area.10 18
In contrast, for our work on miRNAs, we will include both
ipsilateral and contralateral IBCs. We consider this to be
appropriate because our study is motivated by evidence
that breast cancer develops through the accumulation
of molecular abnormalities (eg, structural chromosomal
abnormalities, gene expression alterations) beginning in
normal breast tissue, resulting from exposure to endogenous and environmental factors.51 52 These exposures,
beginning early in and continuing throughout life, can
lead to molecular (and histological) changes in the tissue
of both breasts, rendering them susceptible to the development of cancer,51–53 as evidenced by: (1) the detection
of cancer-
predisposing molecular alterations in histologically normal breast tissue51 54; (2) shared molecular
features in synchronous primary tumours, and concordance of hormone receptor expression status in synchronous and metachronous bilateral breast cancers52 55–57;
(3) the observation that DCIS is often bilateral and
multicentric58 and (4) the increased risk of subsequent
ipsilateral and contralateral IBC in women with DCIS.3 6–9
Nevertheless, we will explore the associations of miRNAs
6

with IBC risk by side of the subsequent IBC (ie, ipsilateral
or contralateral).
Our study has a number of strengths. It was preceded
by extensive pilot work demonstrating the feasibility of
both obtaining clinical information and tissue blocks,
and of performing the molecular assays using FFPE DCIS
tissue. The study is large and will have considerable statistical power, and there is potential for further follow-up
of the cohort to identify additional incident IBC cases.59
The miRNA sequencing protocol that will be employed
was developed for use with archival tissue up to 35 years
old and allows for complete analysis of available transcripts in FFPE tissue60 61; we will validate the sequencing
findings using Taqman qPCR assays, the gold-standard
method. To address possible assay variability, the laboratory technicians undergo intensive training on the molecular assays. Furthermore, we use strict quality control for
RNA/DNA extraction, preparation, and quantification,
and we have built in experimental controls to monitor
the accurate performance of our assays.60 61 Importantly,
the pathology and laboratory staff are blinded to case–
control status.
The study also has some potential limitations. Although
some individuals may be misclassified with respect to
exposure (ie, their status with respect to the results of the
molecular assays), the assays that we will use are highly
sensitive and reproducible.26 60–62 Also, although the study
includes subjects from a wide range of populations across
the USA, caution will be required in generalising the study
findings. However, given that cases and controls will be
selected independently of their status with respect to the
molecular markers of interest, it is unlikely that unavailability or unsuitability of tissue for analysis will bias our
results, and we expect the included subjects to be broadly
representative of the underlying populations. Finally,
a recent report showed that the 21-gene Oncotype DX
breast recurrence score (RS) (Exact Sciences) was associated with increased risk of ipsilateral IBC (based on 19
incident, invasive cases).63 Due to budgetary constraints,
we are unable to incorporate the RS assay into our work.
However, using the Nanostring assay, we will measure
expression of the 21 genes in the RS assay64 and will be
able to examine the association between expression of
these genes and IBC risk.
In conclusion, this study has the potential to provide
insight into the pathogenesis of IBC by identifying molecular changes in DCIS lesions associated with altered IBC
risk. Furthermore, the project has translational potential
given that identification of molecular changes associated with increased IBC risk might enhance the clinical
management of women with DCIS. Specifically, the study
findings might lead both to the development of novel
molecular screening modalities to identify women at
increased risk of IBC and to approaches to prevention
(eg, through risk stratification and tailored surveillance
programmes, and through the development of novel
targeted therapies).
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